title: Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity.
abstract: New anthracycline antibiotics have been isolated from the culture of Streptomyces galilaeus MA144-M1. Among 14 anthracycline compounds, aclacinomycin-A showed the strongest activity in inhibiting leukemia L-1210 and had lower toxicity than others. Antitumor activity of aclacinomycin-A against leukemia L-1210 and P-388, solid sarcoma-180, and lymphosarcoma 6C3HED was examined in comparison with adriamycin and daunomycin. Aclacinomycin-A showed the same degree of activity against leukemia L-1210 and P-388, when administered intraperitoneally, as daunomycin and somewhat less than adriamycin. In oral administration, aclacinomycin-A also exhibited a significant activity on leukemia L-1210. The degree of inhibition of the growth of sarcoma-180 and 6C3HED lymphosarcoma transplanted subcutaneously by aclacinomycin-A was almost the same as that of adriamycin and daunomycin, although the optimal dose was about twice more than adriamycin. Acute cardiotoxicity of aclacinomycin-A by a test using hamsters was more than 10 times lower than that of adriamycin.
mesh_terms: D015250:Aclarubicin / Q000031:analogs & derivatives; D000818:Animals; D000880:Anthraquinones / Q000633:toxicity; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D006224:Cricetinae; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004562:Electrocardiography; D006027:Glycosides / Q000633:toxicity; D006321:Heart / Q000187:drug effects; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008647:Mesocricetus; D051379:Mice; D008815:Mice, Inbred Strains; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013302:Streptomyces / Q000378:metabolism
chemical_list: D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D006027:Glycosides; C011157:aclacinomycins; D015250:Aclarubicin; D004317:Doxorubicin; D003630:Daunorubicin